Buruli Ulcer

04/01/2003 - "By use of a murine model for Buruli ulcer, Mycobacterium ulcerans was found to be susceptible to rifampin, with the MIC being 0.5 to 1 micro g/ml. Three mutants were isolated after rifampin monotherapy. "
02/01/1972 - "Rifampicin in experimental Mycobacterium ulcerans infection."
09/01/1979 - "Mycobacterium ulcerans infection: treatment with rifampin, hyperbaric oxygenation, and heat."
10/01/2002 - "To identify the most active curative treatment of Buruli ulcer, two regimens incorporating the use of rifampin (RIF) were compared with the use of RIF alone in a mouse footpad model of Mycobacterium ulcerans infection. "
01/01/2012 - "Antibiotics combined with surgery may significantly increase treatment success for Mycobacterium ulcerans infections, and fluoroquinolone combined with rifampicin-containing antibiotic regimens can provide an effective and safe oral treatment option."

03/01/2014 - "Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial."
07/01/2007 - "[Streptomycin injections for the treatment of Mycobacterium ulcerans (Buruli ulcer) in a rural health zone in the Democratic Republic of the Congo]."
11/01/2007 - "Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)."
01/01/2013 - "Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review."
10/01/2010 - "First-line therapy for Buruli ulcer is rifampin + streptomycin, sometimes with surgery, but improved regimens are needed. "

07/01/2006 - "Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer."
05/01/2009 - "Since this is the first structural work regarding the interactions of SigC protein and its promoter DNA, this study may contribute in the realm of structure based drug design approaches to produce drugs against this harmful organism to control its proliferation and spreading of Buruli ulcer."
01/01/2015 - "shinshuense DNA from a water channel in familial Buruli ulcer cases in Japan."
04/01/2012 - "We compared two DNA extraction methods (a semiautomated method using a Maxwell kit and a modified Boom method) and three amplification procedures (a single-step PCR, a nested PCR, and a real-time quantitative PCR) on 74 surgical tissue specimens from patients with clinically suspected Buruli ulcer. "
04/01/2012 - "Effects of decontamination, DNA extraction, and amplification procedures on the molecular diagnosis of Mycobacterium ulcerans disease (Buruli ulcer)."

06/01/2014 - "In recent years, first-line therapy for Mycobacterium ulcerans infection in French Guiana has consisted of antibiotics active against this organism. "
10/01/2011 - "Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?"
02/20/2010 - "Should antibiotics be given for Buruli ulcer?"
11/01/2014 - "Buruli ulcer is a stigmatising disease treated with antibiotics and wound care, and sometimes surgical intervention is necessary. "
01/01/2013 - "Towards rational use of antibiotics for suspected secondary infections in Buruli ulcer patients."

09/01/2015 - "These results suggest that use of BCG as a recombinant vehicle expressing MU antigens represents an effective Buruli ulcer vaccine strategy and warrants further antigen discovery to improve vaccine efficacy. "
10/01/1976 - "Lymphocyte-transformation responses to mycobacterial antigens have been studied, using paired blood and lymph node samples from 'normal' Ugandans, (hernia repairs or orthopaedic cases) or from patients with tuberculosis, Mycobacterium ulcerans infection, or injection abscesses. "
09/01/2001 - "Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer."

09/01/2001 - "Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer."

03/01/2001 - "We can conclude that heparin combined with antimycobacterial drugs--which are active in vitro on Mycobacterium ulcerans--could provide an effective medical treatment for Buruli ulcer."
03/01/2001 - "[Contribution of heparin therapy in the medical treatment of Buruli ulcer apropos of 1 case]."
03/01/2001 - "To verify this assumption, we used a combined therapy with two gold standard medicines in an oedematous form of Buruli ulcer on the face which could not be surgically treated: heparin for its activity on thrombosis and rifampin for its bactericidal activity on Mycobacterium ulcerans. "

11/01/2015 - "We evaluated fluorescent thin layer chromatography (f-TLC) for detection of mycolactone in the laboratory using samples from patients with Buruli ulcer and patients with similar lesions that gave a negative result on PCR for the IS2404 repeat sequence of M. "
02/01/2014 - "Mycolactone is a polyketide macrolide lipid-like secondary metabolite synthesized by Mycobacterium ulcerans, the causative agent of BU (Buruli ulcer), and is the only virulence factor for this pathogen identified to date. "
02/01/2014 - "Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer."
01/01/2014 - "We sought to measure the concentration of mycolactone within lesions of patients with Buruli ulcer before, during and after antibiotic treatment to evaluate its association with the clinical and bacteriological response to therapy. "
04/01/2013 - "Our findings should allow for the rationale design of competitive inhibitors of mycolactone binding to N-WASP, with anti-Buruli ulcer therapeutic potential."

02/01/2003 - "In vivo studies suggest that mycolactone, a polyketide-derived macrolide toxin, plays a major role in the tissue destruction and immune suppression which occur in cases of Buruli ulcer. "
11/21/2012 - "Photochemistry of mycolactone A/B, the causative toxin of Buruli ulcer."
09/07/2012 - "Newly isolated mycolactones correspond to the "oxidized forms" of mycolactone A/B, the causative toxin of Buruli ulcer, isolated from Mycobacterium ulcerans."
01/01/2009 - "Mycolactone A/B is a lipophilic macrocyclic polyketide that is the primary virulence factor produced by Mycobacterium ulcerans, a human pathogen and the causative agent of Buruli ulcer. "
08/01/2008 - "Mycobacterium ulcerans is the causative agent of Buruli ulcer, a rapidly emerging human disease in which mycolactone, a cytotoxic and immunosuppressive macrocyclic polyketide, is responsible for massive skin destruction. "

03/13/2014 - "Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice."
09/01/2014 - "Buruli Ulcer (BU)-HIV co-infection is an important emerging management challenge for BU disease. "
06/01/2014 - "perstans co-infection should be considered in the diagnosis and treatment of Buruli ulcer. "
01/01/2014 - "In West and Central Africa Buruli ulcer (BU) and HIV co-infection is increasingly recognised and management of these two diseases combined is an emerging challenge for which there is little published information. "
01/01/2014 - "Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection."

04/01/2014 - "While traditionally surgery has dominated the clinical management of Buruli ulcer (BU), the introduction of the combination chemotherapy with oral rifampicin and intramuscular streptomycin greatly improved treatment and reduced recurrence rates. "
02/01/2012 - "Combination chemotherapy with rifampin and streptomycin (RIF-STR) for 8 weeks is currently recommended by the WHO as the first-line treatment for Mycobacterium ulcerans infection (Buruli ulcer). "

01/01/2012 - "Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo."
02/01/2012 - "Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model."
09/01/2011 - "Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?"
08/01/2011 - "Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?"
02/01/1957 - "Mycobacterium ulcerans infections; response to chemotherapy in mice."

01/01/2009 - "Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial."
01/01/2009 - "Phase change material for thermotherapy of Buruli ulcer: modelling as an aid to implementation."

12/01/2011 - "In the developing world, leprosy and Buruli ulcer are still significant etiologic factors for amputation. "
08/01/2010 - "Mycobacterium ulcerans infection (Buruli ulcer) causes necrotizing lesions that may lead to scarring, contractures, osteomyelitis, and even amputation. "
01/01/2008 - "Treatment for osteomyelitis-complicating Mycobacterium ulcerans infection typically requires extensive surgery and even amputation, with no reported benefit from adjunctive antibiotics. "

02/01/2004 - "The treatment of Buruli ulcer by excision and grafts is efficient but does not prevent recurrences and new focus from happening and for their prevention, it is necessary to discover pharmaceutical molecules that are efficient on Mycobacterium ulcerans."
02/01/2004 - "[Treatment of Buruli ulcer desease by excision and skin graft]."
01/01/2003 - "After statistical analysis, the following risk factors are associated with Buruli ulcer recurrent cases: patient under 30 years old, previous contact with a watercourse, duration of the disease exceeding 75 days before hospitalization, secondary infection before or after surgery disability, treatment by excision and skin graft, ongoing healing of operated wound. "